Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy:: A pilot study
Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy:: A pilot study
复制标题
DOI：
10.1111/j.1523-5378.2008.00593.x
复制
发表时间：
2008-04-01
期刊：
影响因子：
4.4
通讯作者：
Miniello, Vito Leonardo
中科院分区：
文献类型：
--
作者：
Francavilla, Ruggiero;Lionetti, Elena;Miniello, Vito Leonardo
背景：几项研究报告了益生菌对幽门螺杆菌的抑制作用。目的：测试罗伊氏乳杆菌 ATCC 55730 是否能减少体内幽门螺杆菌负荷，减轻消化不良症状，并影响常规治疗后的根除率。材料和方法：在一项双盲安慰剂对照研究中，40 名幽门螺杆菌阳性受试者每天一次服用罗伊氏乳杆菌，持续 4 周。或安慰剂。所有患者在入院时均进行上消化道内窥镜检查、C-13-尿素呼气试验和幽门螺杆菌粪便抗原测定，并在治疗4周后进行C-13-尿素呼气试验和幽门螺杆菌粪便抗原（用作定性和半定量标志物）。随后对所有人进行序贯治疗。结果：在体内，治疗 4 周后，通过 C-13-尿素呼气试验 delta 值和幽门螺杆菌粪便抗原定量进行半定量评估，罗伊氏乳杆菌减少了幽门螺杆菌负荷 (p < .05)。接受安慰剂的患者没有发现任何变化。与治疗前值相比，罗伊氏乳杆菌给药后胃肠道症状评定量表显着下降（p < .05），而接受安慰剂的患者则不存在这种情况（p = 不显着）。根除率没有差异。结论：罗伊氏乳杆菌有效抑制人类幽门螺杆菌感染，减少消化不良症状的发生。尽管如此，它似乎并不影响抗生素治疗的结果。
Background: Several studies report an inhibitory effect of probiotics on Helicobacter pylori.Aim: To test whether Lactobacillus reuteri ATCC 55730 reduces H. pylori intragastric load in vivo, decreases dyspeptic symptoms, and affects eradication rates after conventional treatment.Materials and Methods: In a double-blind placebo-controlled study, 40 H. pylori-positive subjects were given L. reuteri once a day for 4 weeks or placebo. All underwent upper endoscopy, C-13-urea breath test, and H. pylori stool antigen determination at entry and C-13-urea breath test and H. pylori stool antigen (used as both qualitative and semiquantitative markers) after 4 weeks of treatment. Sequential treatment was administered subsequently to all.Results: In vivo, L. reuteri reduces H. pylori load as semiquantitatively assessed by both C-13-urea breath test delta-value and H. pylori stool antigen quantification after 4 weeks of treatment (p < .05). No change was shown in patients receiving placebo. L. reuteri administration was followed by a significant decrease in the Gastrointestinal Symptom Rating Scale as compared to pretreatment value (p < .05) that was not present in those receiving placebo (p = not significant). No difference in eradication rates was observed.Conclusions: L. reuteri effectively suppresses H. pylori infection in humans and decreases the occurrence of dyspeptic symptoms. Nevertheless, it does not seem to affect antibiotic therapy outcome.